Clinical trial · Observational
A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
Database of Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective and prospective study planned to include NSCLC patients with Leptomeningeal metastasis (LM) and treated with antitumor therapy after 2018, from multiple centers such as the First Affiliated Hospital of Guangzhou Medical University, Guangdong Sanjiu Brain Hospital, etc., aiming to establish a database related to the treatment strategies of LM patients, and to evaluate the efficacy (eg. Overall Survival/Time to Failure) and safety of different treatment strategies of LM patients, etc., as well as the significance of concomitant testing in LM patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningeal Metastasis | Meningeal Carcinomatosis | PROBABILISTIC | 0.70 |
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not applicable- observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival(OS)
- timeFrame
- 6 years
Secondary outcomes (3)
- measure
- Time to failure(TTF)
- timeFrame
- 6 years
- measure
- Change in cerebrospinal fluid and metabolic markers during treatment
- timeFrame
- 6 years
- measure
- Safety during actual clinical treatment
- timeFrame
- 6 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * non-small cell lung cancer patients with Leptomeningeal metastases diagnosed after January 2018; * Patients who underwent antitumor therapy after diagnosis of LM. Exclusion Criteria: * Patients with small cell lung cancer components; * complicated with tumors other than non-small cell lung cancer.
References
Publications (0)
Data not yet available